Mometasone furoate dry powder inhaler for the treatment of asthma

Bibliography

• Moorman J, Zahran H, Truman B, Current asthma prevalence – United States. 2006 – 2008. MMWR Morb Mortal Wkly Rep 2011;60:84-6
   Google Scholar
• Moorman J, Rudd R, Johnson C, National surveillance for asthma – United States, 1980 – 2004. MMWR Surveill Summ 2007;19:1-54
   Google Scholar
• Rabe K, Adachi M, Lai C, Worldwide severity and control of asthma in children and adults: The global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7
   PubMed Web of Science ®Google Scholar
• Broide D, Finkleman M, Bochner B, Advances in mechanisms of asthma, allergy, and immunology in 2010. J Allergy Clin Immunol 2011;127:689-95
   PubMed Web of Science ®Google Scholar
• National Heart Lung and Blood Institute, National Institute of Health. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. August 2007. NIH publication no. 08-4051
   Google Scholar
• Barnes P, Pedersen S, Busse W. Efficacy and Safety of Inhaled Corticosteroids. Am J Respir Crit Care Med 1998;157:S1-53
   Google Scholar
• Bennett P, Brown M. Clinical pharmacology. 9th edition. Elsevier Health Sciences; New York: 2003
   Google Scholar
• Schering Corporation. Asmanex® Twisthaler® (mometasone furoate inhalation powder) full prescribing information, 2010. Available from: www.asmanex.com [Last accessed 12 May 2011]
   Google Scholar
• Yang T, Li S, Wyka B, Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001;14:487-94
   PubMedGoogle Scholar
• Stellato C, Atsuta J, Bickel C, An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy Clin Immunol 1999;104:623-9
   PubMed Web of Science ®Google Scholar
• Crocker I, Church M, Newton S. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines. Ann Allergy Asthma Immunol 1998;80:509-16
   PubMed Web of Science ®Google Scholar
• Umland D, Nahrebne D, Razac S, The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ cells. J Allergy Clin Immunol 1997;100:511-19
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Cutler D, Staudinger H, Once-daily evening dosing of mometasone furoate administered via a dry powder does not adversely affect the hypothalamic–pituitary–adrenal axis. Chest 2010;137:115-21
   Google Scholar
• Affrime M, Kosoglou T, Thonoor C, Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000;118:1538-46
   PubMed Web of Science ®Google Scholar
• Skoner D, Gentile D, Angelini B. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. Allergy Asthma Proc 2010;31:10-19
   PubMed Web of Science ®Google Scholar
• Affrime M, Cuss F, Padhi D, Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000;40:1227-36
   PubMed Web of Science ®Google Scholar
• Pickering H, Pitcarin G, Hirst P, Regionallung deposition of a Technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. Clin Ther 2000;22:1483-93
   PubMed Web of Science ®Google Scholar
• Teng X, Cutler D, Davies N. Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos 2003;24:321-33
   PubMed Web of Science ®Google Scholar
• Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab Dispos 2006;34:225-33
   PubMed Web of Science ®Google Scholar
• Kemp J, Berkowitz R, Miller S, Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000;106:485-92
   PubMed Web of Science ®Google Scholar
• Nayak A, Banov C, Corren J, Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000;84:417-24
   PubMed Web of Science ®Google Scholar
• Karpel J, Busse W, Noonan M, Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 2005;39:1977-83
   PubMed Web of Science ®Google Scholar
• Corren J, Berkowitz R, Murray J, Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003;57:567-72
   PubMed Web of Science ®Google Scholar
• Fish J, Karpel J, Craig T, Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000;106:852-60
   PubMed Web of Science ®Google Scholar
• Karpel J, Nayak A, Lumry W, Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. Respir Med 2007;101:628-37
   PubMed Web of Science ®Google Scholar
• Berger W, Milgrom H, Chervinsky P, Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol 2006;97:672-80
   PubMed Web of Science ®Google Scholar
• Meltzer E, Baena-Cagnani C, Chervinsky P, Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. Pediatr Asthma Allergy Immunol 2007;20:67-81
   Google Scholar
• Noonan M, Leflein J, Corren J, Long-term safety of mometasone furoate administered via a dry powder inhaler in children: results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma. BMC Pediatr 2009;9:43
   Google Scholar
• Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). Medwatch the FDA Safety Information and Adverse Event Reporting Program, September 2010. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/ucm230395.htm [Last accessed 2 July 2011]
   Google Scholar
• Bensch G, Prenner B, Berkowitz R, Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006;96:533-40
   PubMed Web of Science ®Google Scholar
• Noonan M, Karpel J, Bensch G, Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001;86:36-43
   PubMed Web of Science ®Google Scholar
• Zetterstrom O, Dahl R, Lindqvist A, Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler. Respir Med 2008;102:1406-11
   PubMedGoogle Scholar
• Karpel J, D'Urzo A, Lockey R, Inhaled mometasone furoate improves health-related quality of life in patients with persistent asthma. J Asthma 2008;45:747-53
   PubMed Web of Science ®Google Scholar